Spots Global Cancer Trial Database for Hippocampus Avoidance PCI vs PCI
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Hippocampus Avoidance PCI vs PCI
Official Title: Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial
Study ID: NCT01780675
Study Description
Brief Summary: Using Intensity Modulated radiotherapy it is possible to treat the entire brain to standard dosages of whole-brain radiation, while keeping the radiation dose to the hippocampus low. However, a clear relationship between radiation dose and damage to the hippocampal stem cells has not been established yet. This study is initiated to investigate the early and delayed neurotoxicity of PCI and to assess in a randomised design the benefits and risks of sparing the hippocampus in Small Cell Lung Cancer patients who receive PCI.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Universitair Ziekenhuis Antwerpen, Antwerpen, , Belgium
Universitair Ziekenhuis Gent, Gent, , Belgium
Universitair Ziekenhuis Leuven, Leuven, , Belgium
The Netherlands Cancer Institute, Amsterdam, , Netherlands
Academisch Medisch Centrum, Amsterdam, , Netherlands
Catharina Ziekenhuis, Eindhoven, , Netherlands
Universitair Medisch Centrum Groningen, Groningen, , Netherlands
Erasmus MC Cancer Centre, Rotterdam, , Netherlands
Instituut Verbeeten, Tilburg, , Netherlands
Contact Details
Name: Jose Belderbos, MD, PhD
Affiliation: The Netherlands Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
